Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.
暂无分享,去创建一个
Tetsuji Sato | K. Yoneyama | T. Matsushita | K. Nogami | M. Taki | M. Shima | K. Fukutake | R. Kasai | Hiroki Yoshida | H. Hanabusa
[1] J. Oldenburg,et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.
[2] K. Nogami,et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens , 2017, Thrombosis and Haemostasis.
[3] Tetsuji Sato,et al. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. , 2016, The New England journal of medicine.
[4] K. Yoneyama,et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. , 2016, Blood.
[5] K. Nogami,et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. , 2014, Blood.
[6] M. Carcao. Changing paradigm of prophylaxis with longer acting factor concentrates , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.
[7] M. Shima,et al. Anti‐factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation , 2014, Journal of thrombosis and haemostasis : JTH.
[8] A. Iorio,et al. High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance , 2013, Journal of Hematology & Oncology.
[9] T. Igawa,et al. Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity , 2013, PloS one.
[10] C. Witmer,et al. Factor VIII inhibitors in hemophilia A: rationale and latest evidence , 2013, Therapeutic advances in hematology.
[11] Iain Gardner,et al. Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies , 2013, Clinical Pharmacokinetics.
[12] J. Mahlangu,et al. Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[13] I. Leite,et al. Health-related quality of life in hemophilia: results of the Hemophilia-Specific Quality of Life Index (Haem-a-Qol) at a Brazilian blood center , 2013, Revista brasileira de hematologia e hemoterapia.
[14] Tsukasa Suzuki,et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model , 2012, Nature Medicine.
[15] J. Wiedel,et al. Arthrodesis of the ankle and subtalar joints in patients with haemophilic arthropathy , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[16] A. Coppola,et al. Treatment of hemophilia: a review of current advances and ongoing issues , 2010, Journal of blood medicine.
[17] J. Powell. Recombinant factor VIII in the management of hemophilia A: current use and future promise , 2009, Therapeutics and clinical risk management.
[18] Alan R. Cohen,et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.
[19] K. Pasi,et al. Haemophilias A and B , 2003, The Lancet.
[20] M. Mikaelsson,et al. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. , 2002, Seminars in thrombosis and hemostasis.
[21] E G Tuddenham,et al. The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.
[22] F. Loth. [Hemophilic arthropathy]. , 1962, Chirurgia narzadow ruchu i ortopedia polska.